Floatz logo

Fuzuloparib

Cardiovascular Risk Factor

Tulane UniversityPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cardiovascular Risk Factor cohort.

Asset / SponsorPhaseRating
Lerodalcibep
LIB Therapeutics LLC
Phase 3B
Zeprumetostat
Tulane University
Phase 1/2CCC
MERCAPTOPURINE ANHYDROUS
The University of Texas at Arlington
Phase 1CC
METHOTREXATE
The University of Texas at Arlington
Phase 1CC
Allopurinol
The University of Texas at Arlington
Phase 1CC

View all 9 →

Same molecule, other indications

Fuzuloparib is also rated in:

Obese Patients With Prostate Cancer DiseaseDormant
B
Indicative ·
60 / 100
View asset →
Chronic Postsurgical PainDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →